Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced two upcoming investor events. The company will host its fiscal fourth quarter and year-end 2025 earnings call on May 22, 2025, at 8:00 a.m. ET, where it will discuss financial results for the period ending March 31, 2025. Additionally, Replimune will hold an Investor Day on June 24, 2025, starting at 10:00 a.m. ET, targeted at analysts and institutional investors. Both events will be available via webcast, with replays accessible through the company's investor relations website.
Replimune Group (NASDAQ: REPL), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di nuove immunoterapie oncolitiche, ha annunciato due prossimi eventi per investitori. La società terrà la conference call sui risultati finanziari del quarto trimestre fiscale e dell'intero anno 2025 il 22 maggio 2025 alle 8:00 ET, durante la quale discuterà i risultati finanziari relativi al periodo terminato il 31 marzo 2025. Inoltre, Replimune organizzerà un Investor Day il 24 giugno 2025 a partire dalle 10:00 ET, rivolto ad analisti e investitori istituzionali. Entrambi gli eventi saranno disponibili in webcast, con le registrazioni accessibili tramite il sito web delle relazioni con gli investitori della società.
Replimune Group (NASDAQ: REPL), una empresa biotecnológica en fase clínica centrada en el desarrollo de nuevas inmunoterapias oncolíticas, ha anunciado dos próximos eventos para inversores. La compañía llevará a cabo su llamada de resultados del cuarto trimestre fiscal y cierre del año 2025 el 22 de mayo de 2025 a las 8:00 a.m. ET, donde discutirá los resultados financieros del periodo que finaliza el 31 de marzo de 2025. Además, Replimune realizará un Día del Inversor el 24 de junio de 2025, comenzando a las 10:00 a.m. ET, dirigido a analistas e inversores institucionales. Ambos eventos estarán disponibles por webcast, con repeticiones accesibles a través del sitio web de relaciones con inversores de la empresa.
Replimune Group (NASDAQ: REPL)은 혁신적인 종양 용해 면역치료제 개발에 주력하는 임상 단계 바이오테크 기업으로, 두 건의 투자자 행사를 발표했습니다. 회사는 2025년 5월 22일 오전 8시(동부시간)에 2025 회계연도 4분기 및 연말 실적 컨퍼런스 콜을 개최하여 2025년 3월 31일로 마감된 기간의 재무 결과를 논의할 예정입니다. 또한, Replimune은 2025년 6월 24일 오전 10시(동부시간)부터 애널리스트 및 기관 투자자를 대상으로 하는 투자자 데이를 진행합니다. 두 행사 모두 웹캐스트로 제공되며, 회사 투자자 관계 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Replimune Group (NASDAQ : REPL), une société biotechnologique en phase clinique spécialisée dans le développement de nouvelles immunothérapies oncolytiques, a annoncé deux événements à venir pour les investisseurs. La société tiendra sa conférence téléphonique sur les résultats du quatrième trimestre fiscal et de l'année 2025 le 22 mai 2025 à 8h00 ET, au cours de laquelle elle présentera les résultats financiers pour la période se terminant le 31 mars 2025. De plus, Replimune organisera une Journée Investisseurs le 24 juin 2025 à partir de 10h00 ET, destinée aux analystes et aux investisseurs institutionnels. Les deux événements seront accessibles en webcast, avec des rediffusions disponibles sur le site des relations investisseurs de la société.
Replimune Group (NASDAQ: REPL), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger onkolytischer Immuntherapien spezialisiert hat, hat zwei bevorstehende Investorenveranstaltungen angekündigt. Das Unternehmen wird am 22. Mai 2025 um 8:00 Uhr ET seine Ergebnispräsentation für das vierte Quartal und das Gesamtjahr 2025 abhalten, bei der die Finanzergebnisse für den Zeitraum bis zum 31. März 2025 besprochen werden. Zusätzlich wird Replimune am 24. Juni 2025 ab 10:00 Uhr ET einen Investorentag für Analysten und institutionelle Investoren veranstalten. Beide Veranstaltungen werden per Webcast übertragen, mit Wiederholungen, die über die Investor-Relations-Website des Unternehmens abrufbar sind.
- None.
- None.
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025.
Fiscal Fourth Quarter Earnings
Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer section should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advise to join 15 minutes prior to the start time.
Investor Day Event
Replimune will host an Investor Day for analysts and institutional investors on Tuesday, June 24, 2025, beginning at 10:00 a.m. ET. The event will be live-streamed and accessible via Replimune’s Investor and Media page at https://ir.replimune.com.
A replay will be available in the Events and Presentation section of the Investor Relations page at https://ir.replimune.com.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
When will Replimune (REPL) report its Q4 and fiscal year 2025 earnings?
When is Replimune's (REPL) Investor Day 2025?
How can investors access Replimune's (REPL) earnings call and Investor Day?
What is Replimune's (REPL) main business focus?
